Lipoprotein management in patients with cardiometabolic risk

Consensus statement from the American diabetes association and the american college of cardiology foundation

John D. Brunzell, Michael Davidson, Curt D. Furberg, Ronald B Goldberg, Barbara V. Howard, James H. Stein, Joseph L. Witztum, M. Sue Kirkman

Research output: Contribution to journalArticle

417 Citations (Scopus)

Abstract

Patients with cardiometabolic risk factors represent a group at high lifetime risk for CVD. These patients frequently have dyslipoproteinemia (low HDL cholesterol, increased triglycerides, and/or an increased number of small LDL particles). We recommend an assessment of global risk followed by a multifactorial risk reduction strategy for such individuals targeting each risk factor and emphasizing both lifestyle and pharmacologic therapy. In terms of dyslipoproteinemia, we recommend the following: Statin therapy for the majority of dyslipoproteinemic adult patients with CMR For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective A concerted, multifaceted, public health effort, focused on lifestyle mod-ification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.

Original languageEnglish
Pages (from-to)811-822
Number of pages12
JournalDiabetes Care
Volume31
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

Cardiology
Lipoproteins
Consensus
Dyslipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apolipoproteins B
Therapeutics
Life Style
Risk Reduction Behavior
LDL Cholesterol
HDL Cholesterol
Triglycerides
Public Health
Cholesterol
Clinical Trials
Costs and Cost Analysis
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Lipoprotein management in patients with cardiometabolic risk : Consensus statement from the American diabetes association and the american college of cardiology foundation. / Brunzell, John D.; Davidson, Michael; Furberg, Curt D.; Goldberg, Ronald B; Howard, Barbara V.; Stein, James H.; Witztum, Joseph L.; Kirkman, M. Sue.

In: Diabetes Care, Vol. 31, No. 4, 01.04.2008, p. 811-822.

Research output: Contribution to journalArticle

Brunzell, John D. ; Davidson, Michael ; Furberg, Curt D. ; Goldberg, Ronald B ; Howard, Barbara V. ; Stein, James H. ; Witztum, Joseph L. ; Kirkman, M. Sue. / Lipoprotein management in patients with cardiometabolic risk : Consensus statement from the American diabetes association and the american college of cardiology foundation. In: Diabetes Care. 2008 ; Vol. 31, No. 4. pp. 811-822.
@article{6a008b5f2b934f1a86ffcf31981333c5,
title = "Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American diabetes association and the american college of cardiology foundation",
abstract = "Patients with cardiometabolic risk factors represent a group at high lifetime risk for CVD. These patients frequently have dyslipoproteinemia (low HDL cholesterol, increased triglycerides, and/or an increased number of small LDL particles). We recommend an assessment of global risk followed by a multifactorial risk reduction strategy for such individuals targeting each risk factor and emphasizing both lifestyle and pharmacologic therapy. In terms of dyslipoproteinemia, we recommend the following: Statin therapy for the majority of dyslipoproteinemic adult patients with CMR For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective A concerted, multifaceted, public health effort, focused on lifestyle mod-ification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.",
author = "Brunzell, {John D.} and Michael Davidson and Furberg, {Curt D.} and Goldberg, {Ronald B} and Howard, {Barbara V.} and Stein, {James H.} and Witztum, {Joseph L.} and Kirkman, {M. Sue}",
year = "2008",
month = "4",
day = "1",
doi = "10.2337/dc08-9018",
language = "English",
volume = "31",
pages = "811--822",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Lipoprotein management in patients with cardiometabolic risk

T2 - Consensus statement from the American diabetes association and the american college of cardiology foundation

AU - Brunzell, John D.

AU - Davidson, Michael

AU - Furberg, Curt D.

AU - Goldberg, Ronald B

AU - Howard, Barbara V.

AU - Stein, James H.

AU - Witztum, Joseph L.

AU - Kirkman, M. Sue

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Patients with cardiometabolic risk factors represent a group at high lifetime risk for CVD. These patients frequently have dyslipoproteinemia (low HDL cholesterol, increased triglycerides, and/or an increased number of small LDL particles). We recommend an assessment of global risk followed by a multifactorial risk reduction strategy for such individuals targeting each risk factor and emphasizing both lifestyle and pharmacologic therapy. In terms of dyslipoproteinemia, we recommend the following: Statin therapy for the majority of dyslipoproteinemic adult patients with CMR For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective A concerted, multifaceted, public health effort, focused on lifestyle mod-ification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.

AB - Patients with cardiometabolic risk factors represent a group at high lifetime risk for CVD. These patients frequently have dyslipoproteinemia (low HDL cholesterol, increased triglycerides, and/or an increased number of small LDL particles). We recommend an assessment of global risk followed by a multifactorial risk reduction strategy for such individuals targeting each risk factor and emphasizing both lifestyle and pharmacologic therapy. In terms of dyslipoproteinemia, we recommend the following: Statin therapy for the majority of dyslipoproteinemic adult patients with CMR For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective A concerted, multifaceted, public health effort, focused on lifestyle mod-ification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.

UR - http://www.scopus.com/inward/record.url?scp=44649098307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649098307&partnerID=8YFLogxK

U2 - 10.2337/dc08-9018

DO - 10.2337/dc08-9018

M3 - Article

VL - 31

SP - 811

EP - 822

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -